Health&Beauty- Page 32

The FINANCIAL -- Doctors certainly don't need a statistically valid sample size to prove it: Young children aren't thrilled with doctors' visits, and their ensuing fear can detract from parents' interactions with the care team.

The FINANCIAL -- The government is stepping up its efforts to snuff out electronic cigarette use among young people, offering an opportunity for doctors of optometry to reiterate to their patients smoking's health hazards, including to their eyes.

The FINANCIAL -- Pumpkins are not only good for carving and baking pies, but they're also good for your eyes.Pumpkin, a carotenoid, is rich in nutrients linked to eye and overall health, including age-related macular degeneration (AMD) and cataracts.

The FINANCIAL -- Healthcare complaints made by patients can provide unique insight on aspects of healthcare delivery not easily evaluated by hospitals, a new study from the London School of Economics and Political Science (LSE) has found.

The FINANCIAL -- America's opioid abuse epidemic won't get better without a clear, concerted public health intervention, which is why the U.S. Surgeon General has recently updated guidance.

The FINANCIAL -- TOKYO and San Francisco, October 1, 2018 - Astellas Pharma Inc and FibroGen, Inc. announced that Astellas submitted a New Drug Application (NDA) for marketing approval in Japan of roxadustat for the treatment of anemia associated with Chronic Kidney

The FINANCIAL -- On the occasion of World Heart Day, Eurostat data highlight the extent to which heart attacks are the cause of death in the European Union (EU). In 2015, in the EU as a whole, heart attacks were reported as

The FINANCIAL -- Published in the journal Optometry & Vision Science, the study illustrated how faster eye-hand visual motor reaction time (EH-VMRT) among professional baseball players significantly correlated with better plate discipline batting metrics, such as swinging at more pitches inside and

The FINANCIAL -- Amgen announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for BLINCYTO (blinatumomab) for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). BLINCYTO was developed in Japan by Amgen Astellas BioPharma

The FINANCIAL -- Leverkusen, September 25, 2018 – No large-scale study has ever found a link between glyphosate and honey bee health issues.